{"nctId":"NCT01109316","briefTitle":"Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use","startDateStruct":{"date":"2010-04"},"conditions":["Diabetes Mellitus, Type 1"],"count":132,"armGroups":[{"label":"Insulin Lispro 2 Day","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Insulin lispro 2 day reservoir in-use"]},{"label":"Insulin Lispro 6 Day","type":"EXPERIMENTAL","interventionNames":["Drug: Insulin lispro 6 day reservoir in-use"]},{"label":"Insulin Aspart 6 Day","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Insulin aspart 6 day reservoir in-use"]}],"interventions":[{"name":"Insulin lispro 2 day reservoir in-use","otherNames":["LY275585","Humalog"]},{"name":"Insulin lispro 6 day reservoir in-use","otherNames":["LY275585","Humalog"]},{"name":"Insulin aspart 6 day reservoir in-use","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosed with type 1 diabetes (World Health Organization criteria) for at least 24 months.\n* Treated with continuous subcutaneous insulin infusion therapy for the previous 6 months.\n* Mean total daily insulin dose for 3 days prior to screening equal to or less than 46 units/day using a 300-unit reservoir or less than or equal to 26 units/day using a 180 unit reservoir.\n* Baseline body mass index (BMI) less than or equal to 35.0 kg/m\\^2.\n* Baseline glycosylated hemoglobin (HbA1c) 5% to 9%.\n\nExclusion Criteria:\n\n* Impaired renal function (serum creatinine greater than or equal to 2.0 milligrams per deciliter \\[mg/dL\\]).\n* Legal blindness.\n* Have had any episode of hypoglycemic coma, seizures, or disorientation in the 12 months prior to screening.\n* Have had hypoglycemia unawareness (routinely asymptomatic at blood glucose (BG) less than 45 mg/dL) in the 12 months prior to screening.\n* Have had any emergency room visits or hospitalizations due to poor glucose control in the 12 months prior to screening.\n* Have had a pump-related infusion site abscess in the 12 months prior to screening.\n* Have had multiple, clinically significant occlusions as judged by the investigator.\n* Have had any infection with staphylococcus aureus in the past 5 years.\n* Have one of the following concomitant diseases: presence of clinically significant hematologic, oncologic, renal, cardiac, hepatic, or gastrointestinal disease, or any other serious disease considered by the investigator to be exclusionary.\n* Patients with malignancy other than basal cell or squamous cell skin cancer who have not yet been treated, are currently being treated, or who were diagnosed less than 5 years ago.\n* Have had a blood transfusion or severe blood loss within 3 months prior to screening, or have known hemoglobinopathy, hemolytic anemia or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with HbA1c methodology.\n* Are receiving chronic (lasting longer than 14 consecutive days) systemic glucocorticoid therapy (excluding topical, intra-articular, intraocular and inhaled prescriptions), or have received such therapy within the 4 weeks immediately preceding screening.\n* Have an irregular sleep/wake cycle (for example, patients who sleep during the day and work during the night), in the investigator's opinion.\n* Have known hypersensitivity or allergy to any of the study insulins or their excipients.\n* Are breastfeeding or pregnant, or intend to become pregnant during the course of the study, or are sexually active women of childbearing potential not actively practicing birth control by a method determined by the investigator to be medically acceptable.\n* Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug or device (other than the study drug/device used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.\n* Have previously completed or withdrawn from this study after having signed the informed consent document (ICD).\n* Are unwilling or unable to comply with the use of a data collection device to directly record data from the patient.","healthyVolunteers":false,"sex":"ALL","minimumAge":"13 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean of Last Five 7-point Self Monitored Blood Glucose (SMBG) Taken on Day 6 for Insulin Lispro 6D and Day 2 for Insulin Lispro 2D and Day 6 for Insulin Aspart 6D Pump Reservoir In-use","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.03","spread":"2.17"},{"groupId":"OG001","value":"9.33","spread":"2.31"},{"groupId":"OG002","value":"8.72","spread":"1.82"}]}]}]},{"type":"SECONDARY","title":"Mean SMBG","description":"Mean SMBG for combined periods; all reported SMBG values on days 1-6 for Insulin Lispro 6 Day and Insulin Aspart 6 Day, and days 1-2 for Insulin Lispro 2 Day.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.79","spread":"2.73"},{"groupId":"OG001","value":"9.01","spread":"2.87"},{"groupId":"OG002","value":"8.83","spread":"2.71"}]}]}]},{"type":"SECONDARY","title":"Mean Daily Insulin Dose (Total, Basal, and Bolus)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.33","spread":"5.88"},{"groupId":"OG001","value":"14.51","spread":"6.33"},{"groupId":"OG002","value":"14.44","spread":"6.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.62","spread":"9.32"},{"groupId":"OG001","value":"18.77","spread":"8.89"},{"groupId":"OG002","value":"18.34","spread":"8.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.36","spread":"10.28"},{"groupId":"OG001","value":"32.37","spread":"10.12"},{"groupId":"OG002","value":"31.99","spread":"10.15"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 8 Weeks Endpoint for Each Treatment in Hemoglobin A1c (HbA1c) Values","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"0.59"},{"groupId":"OG001","value":"0.06","spread":"0.56"},{"groupId":"OG002","value":"0.00","spread":"0.53"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieve or Maintain an HbA1c Less Than or Equal to 6.5% and Less Than 7%","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"38","spread":null},{"groupId":"OG002","value":"44","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Hyperglycemia","description":"Hyperglycemia was defined as an event with (1) a measured blood glucose concentration \\>250 milligrams per deciliter (mg/dL) (13.9 mmol/L) and ≥3 hours after eating, or (2) a measured blood glucose concentration \\>300 mg/dL (16.7 mmol/L) and \\<3 hours after eating.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null},{"groupId":"OG001","value":"98.4","spread":null},{"groupId":"OG002","value":"98.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Hyperglycemic Episode Rate Per 30 Days","description":"Hyperglycemia was defined as an episode with (1) a measured blood glucose concentration \\>250 milligrams per deciliter (mg/dL) (13.9 mmol/L) and ≥3 hours after eating, or (2) a measured blood glucose concentration \\>300 mg/dL (16.7 mmol/L) and \\<3 hours after eating. Rate is presented as the number of hyperglycemic episodes adjusted for 30 days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.91","spread":"12.78"},{"groupId":"OG001","value":"16.91","spread":"13.98"},{"groupId":"OG002","value":"15.76","spread":"12.04"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Pump Complications","description":"Overall Pump Complications were any combination of: tubing clogged, kinked, disconnected, pulled out, blood in tubing; too much heat, too much cold, empty reservoir, low battery, occlusion alarm, no delivery alarm; at site - skin abscess, excessive redness, swelling (not nodule), bleeding, bruising; reservoir change (infusion set change reason only); and other. When either a reservoir change or an infusion set change was reported, participants were questioned whether change was early (prior to 6 days for L6D or A6D, or prior to 2 days for L2D). If 'yes', then recorded as premature change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.8","spread":null},{"groupId":"OG001","value":"38.6","spread":null},{"groupId":"OG002","value":"36.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.6","spread":null},{"groupId":"OG001","value":"59.1","spread":null},{"groupId":"OG002","value":"56.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Pump Complication Rate Per 30 Days","description":"Overall Pump Complications were any combination of: tubing clogged, kinked, disconnected, pulled out, blood in tubing; too much heat, too much cold, empty reservoir, low battery, occlusion alarm, no delivery alarm; at site - skin abscess, excessive redness, swelling (not nodule), bleeding, bruising; reservoir change (infusion set change reason only); and other. When either a reservoir change or an infusion set change was reported, participants were questioned whether change was early (prior to 6 days for L6D or A6D, or prior to 2 days for L2D). If 'yes', then recorded as premature change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"0.34"},{"groupId":"OG001","value":"0.40","spread":"0.76"},{"groupId":"OG002","value":"0.51","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":"0.65"},{"groupId":"OG001","value":"0.84","spread":"1.18"},{"groupId":"OG002","value":"0.94","spread":"1.35"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Hypoglycemia","description":"Hypoglycemia was defined as an event which was associated with\n\n1. reported signs and symptoms of hypoglycemia, and/or\n2. a documented blood glucose (BG) concentration of ≤ 70 mg/dL (3.9 mmol/L).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"99.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Hypoglycemia Episode Rate Per 30 Days","description":"Hypoglycemia was defined as an event which was associated with\n\n1. reported signs and symptoms of hypoglycemia, and/or\n2. a documented blood glucose (BG) concentration of ≤ 70 mg/dL (3.9 mmol/L). Rate is presented as the number of hypoglycemic episodes adjusted for 30 days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.90","spread":"11.13"},{"groupId":"OG001","value":"15.66","spread":"12.29"},{"groupId":"OG002","value":"17.52","spread":"11.76"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 8 Weeks Endpoint for Each Treatment in Weight","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":"2.13"},{"groupId":"OG001","value":"0.34","spread":"2.04"},{"groupId":"OG002","value":"0.65","spread":"2.13"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 8 Weeks Endpoint for Each Treatment in Blood Pressure","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"12.82"},{"groupId":"OG001","value":"0.80","spread":"12.52"},{"groupId":"OG002","value":"-1.07","spread":"12.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"8.24"},{"groupId":"OG001","value":"1.37","spread":"7.62"},{"groupId":"OG002","value":"-0.33","spread":"7.88"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":122},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Oropharyngeal pain","Headache","Nausea"]}}}